Dr. Gregory A. Masters
Claim this profileHelen F Graham Cancer Center
About Gregory A. Masters
Education:
- Obtained an MD from Jefferson Medical College, Philadelphia, PA, in 1985.
Experience:
- Board Certified in Internal Medicine and Medical Oncology.
- Serves as a Clinical Professor of Medicine at Thomas Jefferson University.
- Director of the Lung Cancer Program at the Helen F. Graham Cancer Center & Research Institute.
- Founding member and past president of the International Association for the Study of Lung Cancer (IASLC).
- Held the position of President of the American Society of Clinical Oncology (ASCO) in 2016.
Area of expertise
Breast Cancer
Gregory A. Masters has run 27 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Gregory A. Masters has run 22 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Helen F. Graham Cancer Center
Beebe South Coastal Health Campus
Clinical Trials Gregory A. Masters is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting
2 awards
Phase 3
19 criteria
More about Gregory A. Masters
Clinical Trial Related
7 years of experience running clinical trials · Led 133 trials as a Principal Investigator · 47 Active Clinical Trials
Treatments Gregory A. Masters has experience with
- Carboplatin
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Atezolizumab
- Cisplatin
Breakdown of trials Gregory A. Masters has run
Breast Cancer
Breast cancer
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory A. Masters specialize in?
Gregory A. Masters focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are Stage II.
Is Gregory A. Masters currently recruiting for clinical trials?
Yes, Gregory A. Masters is currently recruiting for 47 clinical trials in Newark Delaware. If you're interested in participating, you should apply.
Are there any treatments that Gregory A. Masters has studied deeply?
Yes, Gregory A. Masters has studied treatments such as Carboplatin, Nivolumab, Paclitaxel.
What is the best way to schedule an appointment with Gregory A. Masters?
Apply for one of the trials that Gregory A. Masters is conducting.
What is the office address of Gregory A. Masters?
The office of Gregory A. Masters is located at: Helen F Graham Cancer Center, Newark, Delaware 19713 United States. This is the address for their practice at the Helen F Graham Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.